logo_ProQR-150x150.png
ProQR Announces First Quarter 2021 Operating and Financial Results
May 06, 2021 07:00 ET | ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022Positive data reported from the Phase 1/2 clinical trial of QR-421a for the...
logo_ProQR-150x150.png
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
March 17, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
February 25, 2021 07:00 ET | ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from...
logo_ProQR-150x150.png
ProQR Announces Third Quarter 2020 Operating and Financial Results
November 16, 2020 07:00 ET | ProQR Therapeutics N.V.
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a...
logo_ProQR-150x150.png
ProQR to Participate in Upcoming Investor Conferences
September 03, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Second Quarter 2020 Operating and Financial Results
August 06, 2020 16:30 ET | ProQR Therapeutics N.V.
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;Strategic...
logo_ProQR-150x150.png
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
July 21, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
July 14, 2020 16:30 ET | ProQR Therapeutics N.V.
Extends ProQR’s cash runway into 2023ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 ...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen
July 13, 2020 16:30 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
Logo.jpg
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
June 22, 2020 15:00 ET | Celsion CORP
Lawrenceville, NJ, June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to...